Boehringer Ingelheim abandons biosimilars outside the US


Dan Stanton, Managing editor

November 28, 2018

2 Min Read
Boehringer Ingelheim abandons biosimilars outside the US
Boehringer Ingelheim shuts the doors on biosimilars outside the US. Image: iStock/Malik Evren

German drugmaker Boehringer Ingelheim will not commercialize its approved adalimumab product Cyltezo in Europe and is discontinuing all biosimilar development activities outside the US.

Earlier this month, an article published in Bioprocess Insider considering the impending exit of Big Pharma from the biosimilars space brought a lot of attention from industry and investors. The piece drew on Merck KGaA’s abandonment of its biosimilars programs in 2017 as an example, and now fellow German Big Pharma firm Boehringer Ingelheim is contemplating similar, outside of the US at least.

“Boehringer Ingelheim believes the introduction of high-quality, lower-cost biosimilars is critical for both patients and the sustainability of the healthcare system,” spokesperson Ralph Warsinsky told BioProcess Insider.


Boehringer Ingelheim shuts the doors on biosimilars outside the US. Image: iStock/Malik Evren

However, “at this point in time, future biosimilars activities will be driven out of the US market, including partnership opportunities, while Boehringer Ingelheim is stopping development activities for the rest of the world.”

A snapshot of Boehringer Ingelheim’s biosimilar pipeline webpage from December 2017 shows a version of Roche’s Avastin (bevacizumab), BI 695502, was in Phase III clinical studies, and Cyltezo (BI 695501), a version of AbbVie’s Humira (adalimumab), had been approved. An error message greets website viewers when visiting the page today.

Humira biosimilar

Humira is the top selling drug in the world. In 2017, AbbVie earned $18.4 billion (€16.2 billion) in worldwide sales from the monoclonal antibody, with the US market contributing $12.4 billion.

In 2017, Boehringer Ingelheim’s Cyltezo became the first biosimilar version to be approved in Europe, and the second to be approved in the US. Neither are available, though Warsinsky said only the US product is now expected to be commercialized.

“While Boehringer Ingelheim had planned to bring Cyltezo to patients in the EU, due to the patent litigation with AbbVie in the US, we will not commercialize our biosimilar in the EU,” he said.

Rival biosimilar makers Sandoz, Amgen, Samsung Bioepis and Mylan have all recently launched their adalimumab products in Europe.

In the US, settled lawsuits have led several biosimilar firms to agreeing to launch their adalimumab products from 2023, but Boehringer Ingelheim continues to battle with AbbVie in the courts in efforts to launch Cyltezo earlier than this.

“Our focus is on bringing Cyltezo to the US market and we are committed to making it available to US patients as soon as possible and certainly before 2023.”

UPDATE: Boehringer Ingelheim has confirmed with BioProcess Insider that Cyltezo will be commercialized in the US by Boehringer Ingelheim itself, and not through a marketing partner.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like